Ladenburg analyst Matt Kaplan raised the firm’s price target on Liquidia (LQDA) to $30 from $15 and keeps a Buy rating on the shares, citing updated revenue projections based on the increased clarity on the path toward full approval of Yutrepia after the Court of Appeals Federal Circuit affirmed the Patent Trial and Appeal Board’s written decision for the inter partes review of the ‘793 patent ruling, finding all United Therapeutics’ (UTHR) claims were unpatentable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LQDA:
- U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
- Liquidia director Manning buys 279,330 common shares
- Liquidia prices 3.49M shares at $7.16 in underwritten public offering
- Liquidia Announces Pricing of Public Offering of Common Stock
- Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
